ESRP1 and neoplasm: In melanoma, low ESRP1 expression was correlated with greater tumor-associated immune cytolytic activity and patients with low ESRP1 expression showed a favorable survival, suggesting the potential utility of ESRP1 as a biomarker in predicting response to immunotherapy [22].